0001179110-22-001517.txt : 20220222
0001179110-22-001517.hdr.sgml : 20220222
20220222174052
ACCESSION NUMBER: 0001179110-22-001517
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220217
FILED AS OF DATE: 20220222
DATE AS OF CHANGE: 20220222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SALEKI-GERHARDT AZITA
CENTRAL INDEX KEY: 0001563545
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35565
FILM NUMBER: 22659621
MAIL ADDRESS:
STREET 1: 1 N. WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AbbVie Inc.
CENTRAL INDEX KEY: 0001551152
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 320375147
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
BUSINESS PHONE: (847) 932-7900
MAIL ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
4
1
edgar.xml
FORM 4 -
X0306
4
2022-02-17
0
0001551152
AbbVie Inc.
ABBV
0001563545
SALEKI-GERHARDT AZITA
1 N. WAUKEGAN ROAD
NORTH CHICAGO
IL
60064
0
1
0
0
EVP, Operations
Common Stock, $0.01 par value
2022-02-17
4
A
0
25612
0
A
141896
D
Common Stock, $0.01 par value
2022-02-17
4
A
0
5568
0
A
147464
D
Common Stock, $0.01 par value
2022-02-17
4
A
0
11229
0
A
158693
D
Common Stock, $0.01 par value
2022-02-17
4
A
0
7490
0
A
166183
D
Common Stock, $0.01 par value
2022-02-17
4
A
0
13837
0
A
180020
D
Common Stock, $0.01 par value
2322
I
Profit sharing trust
Common Stock, $0.01 par value
3873
I
By spouse
Option (Right to Buy)
144.54
2022-02-17
4
A
0
35026
0
A
2023-02-17
2032-02-16
Common Stock
35026
35026
D
Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
Represents shares of AbbVie common stock issued under a cliff vesting restricted stock unit award granted to the reporting person on February 17, 2022. The shares will vest in their entirety on the third anniversary of the grant date, subject to the reporting person's continued employment at AbbVie on such date.
Balance in AbbVie Savings program as of January 31, 2022.
The reporting person disclaims beneficial ownership of all securities held by her spouse.
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,676 on February 17, 2023, 11,675 on February 17, 2024, and 11,675 on February 17, 2025.
Steven L. Scrogham, attorney-in-fact for Azita Saleki-Gerhardt
2022-02-22